Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bepotastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 6/20 | 0.55 |
| ▸ | DRD2 | P14416 | 10/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bepotastine SCHEMBL29459 | 0.99 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL30200949 | 0.99 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL29440897 | 0.99 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL5151702 | 0.99 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL726880 | 0.99 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2808049 | 0.98 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2806225 | 0.98 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2807641 | 0.98 | BCHE (0.55) | BCHEDRD2NPC1MLNRNR1I2 | |
| SCHEMBL28391952 | 0.95 | BCHE (0.56) | BCHEDRD2NPC1MLNRNR1I2 | |
| Bepotastine SCHEMBL2804852 | 0.95 | BCHE (0.54) | BCHEDRD2NPC1MLNRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168433-A1 | PROCESS FOR PREPARING BEPOTASTINE AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
| US-20100137367-A1 | NOVEL CRYSTALLINE BEPOTASTINE METAL SALT HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
| EP-2167488-A2 | PROCESS FOR PREPARING BEPOTASTINE AND INTERMEDIATES USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2010-03-31 | — | — | EP | disclosed |
| CN-101679369-A | Process for preparing bepotastine and intermediates used therein | HANMI PHARM IND CO LTD | 2010-03-24 | — | — | CN | disclosed |
| CN-101652358-A | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | HANMI PHARM IND CO LTD KR | 2010-02-17 | — | — | CN | disclosed |
| EP-2144896-A1 | NOVEL CRYSTALLINE BEPOTASTINE METAL SALT HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008153289-A2 | PROCESS FOR PREPARING BEPOTASTINE AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008123701-A1 | NOVEL CRYSTALLINE BEPOTASTINE METAL SALT HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARM. CO., LTD. (KR) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168433-A1 | PROCESS FOR PREPARING BEPOTASTINE AND INTERMEDIATES USED THEREIN | HRH4, HRH2, HRH1 | HRH1 3/4885BCHE 23/4885DRD2 2559/4885 |
| US-20100137367-A1 | NOVEL CRYSTALLINE BEPOTASTINE METAL SALT HYDRATE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HRH1, NOTUM, HRH2 | HRH1 1/4885BCHE 41/4885DRD2 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.